FI50420C - Menetelmä terapeuttisesti aktiivisten 4-pyrimidinyyli-1,4-dihydropyrid iinijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti aktiivisten 4-pyrimidinyyli-1,4-dihydropyrid iinijohdannaisten valmistamiseksi

Info

Publication number
FI50420C
FI50420C FI680267A FI26768A FI50420C FI 50420 C FI50420 C FI 50420C FI 680267 A FI680267 A FI 680267A FI 26768 A FI26768 A FI 26768A FI 50420 C FI50420 C FI 50420C
Authority
FI
Finland
Prior art keywords
pyrimidinyl
preparation
therapeutically active
dihydropyridine derivatives
dihydropyridine
Prior art date
Application number
FI680267A
Other languages
English (en)
Swedish (sv)
Other versions
FI50420B (fi
Inventor
Friedrich Bossert
Wulf Vater
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI50420B publication Critical patent/FI50420B/fi
Application granted granted Critical
Publication of FI50420C publication Critical patent/FI50420C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Hydrogenated Pyridines (AREA)
FI680267A 1967-03-20 1968-02-02 Menetelmä terapeuttisesti aktiivisten 4-pyrimidinyyli-1,4-dihydropyrid iinijohdannaisten valmistamiseksi FI50420C (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEF0051880 1967-03-20

Publications (2)

Publication Number Publication Date
FI50420B FI50420B (fi) 1975-12-01
FI50420C true FI50420C (fi) 1976-03-10

Family

ID=7104983

Family Applications (1)

Application Number Title Priority Date Filing Date
FI680267A FI50420C (fi) 1967-03-20 1968-02-02 Menetelmä terapeuttisesti aktiivisten 4-pyrimidinyyli-1,4-dihydropyrid iinijohdannaisten valmistamiseksi

Country Status (13)

Country Link
US (1) US3511837A (fi)
BE (1) BE712346A (fi)
DE (1) DE1670826A1 (fi)
DK (1) DK119559B (fi)
ES (1) ES351796A1 (fi)
FI (1) FI50420C (fi)
FR (2) FR1557376A (fi)
GB (1) GB1173105A (fi)
IL (1) IL29568A (fi)
NL (1) NL6803565A (fi)
NO (1) NO123348B (fi)
SE (1) SE347263B (fi)
YU (1) YU32464B (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950336A (en) * 1972-03-06 1976-04-13 Bayer Aktiengesellschaft 2,6-diamino-1,4-dihydropyridine derivatives
US3988458A (en) * 1972-03-06 1976-10-26 Bayer Aktiengesellschaft Bicyclic derivatives of 1,4-dihydropyridine 3,5-carboxylic acid esters
DE3022030A1 (de) * 1980-06-12 1981-12-17 Bayer Ag, 5090 Leverkusen 4-thiazol- bzw. 4-imidazol-substituierte, 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
US4833150A (en) * 1985-03-14 1989-05-23 Nelson Research & Development Co. 1,4-dihydropyridines
US4849436A (en) * 1986-03-11 1989-07-18 Nelson Research & Development Co. 1,4-dihydropyridines

Also Published As

Publication number Publication date
IL29568A (en) 1971-12-29
US3511837A (en) 1970-05-12
FR7774M (fi) 1970-03-23
BE712346A (fi) 1968-09-18
DK119559B (da) 1971-01-25
SE347263B (fi) 1972-07-31
FI50420B (fi) 1975-12-01
NL6803565A (fi) 1968-09-23
YU32464B (en) 1974-12-31
GB1173105A (en) 1969-12-03
DE1670826A1 (de) 1971-03-11
NO123348B (fi) 1971-11-01
FR1557376A (fi) 1969-02-14
ES351796A1 (es) 1969-06-16
YU59668A (en) 1974-06-30

Similar Documents

Publication Publication Date Title
FI49300C (fi) Menetelmä terapeuttisesti aktiivisten 1,4-dihydropyridiinijohdannaiste n valmistamiseksi.
FI42712C (fi) Menetelmä terapeuttisesti vaikuttavien bifenyylialkaanijohdannaisten valmistamiseksi
FI49957C (fi) Menetelmä terapeuttisesti vaikuttavien oksiimieetterien valmistamiseks i.
FI49497C (fi) Menetelmä terapeuttisesti vaikuttavien 1-fenoksi-2-3-alkyyliaminopropa anien valmistamiseksi.
FI48727C (fi) Menetelmä asetyyliguanidiinien valmistamiseksi.
FI50707C (fi) Menetelmä uusien farmakologisesti vaikuttavien hydroksisykloheksyyliam iinien valmistamiseksi.
FI49720C (fi) Menetelmä terapeuttisesti vaikuttavien 2-metyyli-3-karbonihappoamidoki noksaliini-di-N-oksidien-(1,4) valmistamiseksi.
FI48930C (fi) Menetelmä 3-(5-nitro-2-furyyli)-2-isoksatsoliinien uusien terapeuttise sti aktiivisten johdannaisten valmistamiseksi.
FI46373C (fi) Menetelmä fenyyliaminopropaanin uusien terapeuttisesti käyttökelpoiste n johdannaisten valmistamiseksi.
FI46960C (fi) Menetelmä terapeuttisesti aktiivisten imidatsolijohdannaisten valmista miseksi
FI48083C (fi) Menetelmä uusien, terapeuttisesti aktiivisten imidatsolijohdannaisten valmistamiseksi
FI45551C (fi) Menetelmä terapeuttisesti käytettävän dehydroepiandrosteroniönantaatin valmistamiseksi.
FI49718C (fi) Menetelmä terapeuttisesti vaikuttavien 2-halogeenimetyyli-3-karbonihap poamidokinoksaliini-di-N-oksidien-(1,4) valmistamiseksi.
FI50420C (fi) Menetelmä terapeuttisesti aktiivisten 4-pyrimidinyyli-1,4-dihydropyrid iinijohdannaisten valmistamiseksi
FI51175C (fi) Menetelmä terapeuttisesti käytettävien indanyylitiokarbamaattien valmi stamiseksi.
FI49413C (fi) Menetelmä uusien terapeuttisesti vaikuttavien fentiatsiinijohdannaisie n valmistamiseksi.
FI48576C (fi) Menetelmä terapeuttisesti aktiivisten alfa-fluori-malonihappojohdannai sten valmistamiseksi.
FI48190C (fi) Menetelmä terapeuttisesti aktiivisten 10alfa-metoksi-9,10-dihydroergol iinijohdannaisten valmistamiseksi
FI48090C (fi) Menetelmä 1-syaaniaminoalkyyli-2H-1,4-bentsodiatsepiini-2-oni-johdanna isten valmistamiseksi
FI51349C (fi) Menetelmä terapeuttisesti vaikuttavien N-substituoitujen 6,7-bentsomor faanien valmistamiseksi.
FI47357C (fi) Menetelmä terapeuttisesti vaikuttavien 4'-demetyyli-epipodofyllotoksii ni-beta-D-glukosidin johdannaisten valmistamiseksi.
FI45553C (fi) Menetelmä terapeuttisesti käytettävien 16-tiosubstituoitujen 9beta,10a lfa-pregneenien valmistamiseksi
FI46066C (fi) Analogiamenetelmä terapeuttisesti vaikuttavien N,N-dimetyyliamino-etyy li-14beta-hydroksi-5beta-pregn-20-eeni-21-karboksylaattien valmistamis eksi.
FI50879C (fi) Menetelmä terapeuttisesti vaikuttavien substituoitujen 3-aminoasyyliam ino-tiofeenien valmistamiseksi.
FI49038C (fi) Analogiamenetelmä uusien, farmakologisesti aktiivisten 4-fenyyli-1H-ki natsoliini-2-oni-johdannaisten valmistamiseksi.